Sean Flynn Sells 15,000 Shares of Vericel (NASDAQ:VCEL) Stock

Vericel Corporation (NASDAQ:VCEL) insider Sean Flynn sold 15,000 shares of the stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $40.21, for a total value of $603,150.00. Following the sale, the insider directly owned 1,647 shares of the company’s stock, valued at approximately $66,225.87. The trade was a 90.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Vericel Price Performance

VCEL traded up $0.37 during trading on Monday, reaching $40.47. The company had a trading volume of 595,944 shares, compared to its average volume of 605,152. Vericel Corporation has a 12 month low of $28.95 and a 12 month high of $43.57. The business’s fifty day moving average price is $35.32 and its 200 day moving average price is $35.62. The company has a market cap of $2.07 billion, a P/E ratio of 96.36 and a beta of 1.12.

Vericel (NASDAQ:VCEL) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.03. Vericel had a net margin of 7.35% and a return on equity of 6.41%. The company had revenue of $68.43 million during the quarter, compared to analysts’ expectations of $63.68 million. During the same quarter in the prior year, the company earned ($0.23) earnings per share. The business’s quarterly revenue was up 30.1% compared to the same quarter last year. As a group, sell-side analysts predict that Vericel Corporation will post 0.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Huntington National Bank lifted its position in Vericel by 51.3% during the 3rd quarter. Huntington National Bank now owns 805 shares of the biotechnology company’s stock worth $25,000 after buying an additional 273 shares in the last quarter. State of Alaska Department of Revenue grew its holdings in shares of Vericel by 1.4% in the 4th quarter. State of Alaska Department of Revenue now owns 25,744 shares of the biotechnology company’s stock valued at $927,000 after acquiring an additional 353 shares in the last quarter. Osaic Holdings Inc. grew its holdings in shares of Vericel by 13.7% in the 2nd quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company’s stock valued at $125,000 after acquiring an additional 353 shares in the last quarter. California State Teachers Retirement System increased its position in shares of Vericel by 0.8% in the second quarter. California State Teachers Retirement System now owns 45,404 shares of the biotechnology company’s stock valued at $1,932,000 after acquiring an additional 382 shares during the last quarter. Finally, Commonwealth Equity Services LLC increased its position in shares of Vericel by 3.6% in the fourth quarter. Commonwealth Equity Services LLC now owns 11,698 shares of the biotechnology company’s stock valued at $421,000 after acquiring an additional 410 shares during the last quarter.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Truist Financial lowered their target price on Vericel from $48.00 to $42.00 and set a “buy” rating for the company in a report on Wednesday, April 15th. HC Wainwright restated a “buy” rating and issued a $64.00 price target on shares of Vericel in a report on Friday, May 8th. Weiss Ratings raised Vericel from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 16th. Leerink Partners reiterated an “outperform” rating and set a $46.00 price objective on shares of Vericel in a report on Tuesday, March 10th. Finally, Wall Street Zen lowered Vericel from a “buy” rating to a “hold” rating in a research report on Sunday, June 14th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $52.50.

About Vericel

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.